Nov 22, 2022 | Press Releases
– Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 – Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022...
Nov 21, 2022 | Press Releases
– RP1208 is in preclinical development for the potential treatment of depression and obesity – – Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan –...
Nov 14, 2022 | Press Releases
– Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial – – Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 – – $23.2 Million in Cash as of September 30, 2022...
Oct 31, 2022 | Press Releases
– Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 – – Enrollment on pace, with over 30% enrolled in the United States – – Topline data for RECOVER evaluating brilaroxazine for...
Oct 13, 2022 | Press Releases
CUPERTINO, CA / October 13, 2022 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Sep 26, 2022 | Press Releases
CUPERTINO, Calif., Sept. 26, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
